<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03325283</url>
  </required_header>
  <id_info>
    <org_study_id>CIP_00104, Rev 02, 23 May 2017</org_study_id>
    <nct_id>NCT03325283</nct_id>
  </id_info>
  <brief_title>The PROTEMBO SF Trial</brief_title>
  <official_title>Cerebral Protection in Transcatheter Aortic Valve Replacement</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Protembis GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>MAXIS, LLC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Protembis GmbH</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The PROTEMBO SF Trial is a prospective, observational, multi-center, intention-to-treat study
      of the safety and feasibility of the ProtEmbo Cerebral Protection System in subjects with
      severe symptomatic native aortic valve stenosis indicated for TAVR.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The PROTEMBO SF Trial is a prospective, single arm, observational, multi-center,
      intention-to-treat study of the safety and feasibility of the ProtEmbo Cerebral Protection
      System in subjects with severe symptomatic native aortic valve stenosis indicated for TAVR.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 9, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Human patients indicated for transcatheter aortic valve replacement</intervention_model_description>
    <primary_purpose>Device Feasibility</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Procedural success</measure>
    <time_frame>1 day</time_frame>
    <description>defined as successful access, delivery to, deployment within, and retrieval of the ProtEmbo System from the aortic arch as well as adequate coverage of side branch vessels and maintenance of position for duration of the TAVR procedure.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>In-hospital procedural safety up to 7 days</measure>
    <time_frame>7 days</time_frame>
    <description>defined as occurrence of all Major Adverse Cardiac and Cerebrovascular Events (MACCEs) defined by the Valve Academic Research Consortium (VARC-2) criteria, including device-related safety outcomes (peri-procedural rates of TIA, all-cause mortality, all stroke (disabling and non-disabling), life-threatening (or disabling) bleeding, acute kidney injury (stage 2 or 3), major vascular complications and other device related complications).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stroke severity</measure>
    <time_frame>3 days</time_frame>
    <description>quantified according to the National Institutes of Health Stroke Scale (NIHSS) score at day 3 (±2).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stroke severity</measure>
    <time_frame>30 days</time_frame>
    <description>quantified according to the National Institutes of Health Stroke Scale (NIHSS) score at 30 days (±7).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of Serious Adverse Events</measure>
    <time_frame>3 days</time_frame>
    <description>as defined by ISO 14155 up to 3 (±2) days or discharge (whichever is later) and 30 days (±7).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of Serious Adverse Events</measure>
    <time_frame>30 days</time_frame>
    <description>as defined by ISO 14155 at 30 days (±7).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of new cerebral lesions</measure>
    <time_frame>3 days</time_frame>
    <description>defined by diffusion weighted magnetic resonance imaging (DW-MRI) prior to discharge at day 3 (±2) compared to baseline and/ or historical control group;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of new cerebral lesions</measure>
    <time_frame>3 days</time_frame>
    <description>defined by diffusion weighted magnetic resonance imaging (DW-MRI) prior to discharge at day 3 (±2) compared to baseline and/ or historical control group;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of new cerebral lesions</measure>
    <time_frame>3 days</time_frame>
    <description>defined by diffusion weighted magnetic resonance imaging (DW-MRI) prior to discharge at day 3 (±2) compared to baseline and/ or historical control group;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of new cerebral lesions</measure>
    <time_frame>30 days</time_frame>
    <description>defined by Diffusion weighted- and FLAIR-MRI sequence at 30 days (±7 days).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of new cerebral lesions</measure>
    <time_frame>30 days</time_frame>
    <description>defined by Diffusion weighted- and FLAIR-MRI sequence at 30 days (±7 days).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of new cerebral lesions</measure>
    <time_frame>30 days</time_frame>
    <description>defined by Diffusion weighted- and FLAIR-MRI sequence at 30 days (±7 days).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive function</measure>
    <time_frame>30 days</time_frame>
    <description>defined as change in neurocognitive testing at 30 (+/- 7) days post-procedure using MoCA post-procedure compared to baseline.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Aortic Stenosis</condition>
  <arm_group>
    <arm_group_label>Protembo device treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who consent to participate in the PROTEMBO SF Trial and in whom the ProtEmbo Cerebral Protection System is used or is attempted to be used.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ProtEmbo Cerebral Protection System</intervention_name>
    <description>A catheter-based embolic deflection device will be positioned in the arch of the aorta to prevent debris liberated during the TAVR procedure from entering the three major vessels of the aortic arch.</description>
    <arm_group_label>Protembo device treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Approved indications for commercially available transcatheter aortic valves by
             transfemoral route. Refer to the selected valve IFU for additional details.

          2. Compatible left subclavian artery (≥ 4 mm diameter) without significant stenosis (&gt;
             70%) and distance between the origin of left subclavian artery and valve plain is ≥
             90mm as determined by Multi-Slice Computed Tomography (MSCT) scan or equivalent
             imaging modality.

          3. The subject and the treating physician agree that the subject will undergo the
             scheduled pre-procedural testing and return for all required post-procedure follow-up
             visits.

          4. The subject has been informed of the nature of the trial, agrees to its provisions and
             has provided written informed consent as approved by the national or local regulatory
             authorities of the respective clinical site.

          5. Subject is a minimum of 18 years of age.

        Exclusion Criteria:

          1. Left upper limb vasculature precluding 6Fr sheath (radial or brachial access).

          2. Inadequate circulation to the left extremity as evidenced by signs of artery occlusion
             (modified Allen's test) or absence of radial/ brachial pulse.

          3. Hemodialysis shunt, graft, or arterio-venous fistula involving the upper extremity
             vasculature.

          4. TAVR conducted via other than transfemoral access (subclavian, axillar, transapical,
             transaortic, carotid or transcaval).

          5. Evidence of an acute myocardial infarction ≤ 1 month before the intended treatment.

          6. Aortic valve is a congenital unicuspid or bicuspid valve.

          7. Mixed aortic valve disease (aortic stenosis and aortic regurgitation with predominant
             aortic regurgitation &gt;3+).

          8. Any therapeutic invasive cardiac procedure resulting in a permanent implant that is
             performed within 30 days of the index procedure (unless part of planned strategy for
             treatment of concomitant coronary artery disease).

          9. Pre-existing prosthetic heart valve in any position, prosthetic ring, or severe
             (greater than 3+) mitral insufficiency.

         10. Blood dyscrasias as defined: Leukopenia, acute anemia, thrombocytopenia, history of
             bleeding diathesis or coagulopathy.

         11. Hemodynamic instability requiring inotropic support or mechanical heart assistance.

         12. Need for emergency surgery for any reason.

         13. Severe hypertrophic cardiomyopathy with or without obstruction.

         14. Severe ventricular dysfunction with LVEF ≤30%.

         15. Echocardiographic evidence of intracardiac or aortic mass, thrombus, or vegetation.

         16. Symptomatic or asymptomatic severe (≥ 70%) occlusive carotid disease requiring
             concomitant CEA/ stenting.

         17. Subject has undergone carotid stenting or carotid endarterectomy within the previous 6
             weeks.

         18. Active peptic ulcer or upper GI bleeding within the prior 3 months.

         19. A known hypersensitivity or contraindication to aspirin, heparin, ticlopidine, or
             clopidogrel, device component material, or sensitivity to contrast media, which cannot
             be adequately pre-medicated.

         20. Recent (within 6 months) CVA or a TIA.

         21. Renal insufficiency (creatinine &gt; 3.0 mg/ dL or GFR &lt; 30) and/ or renal replacement
             therapy at the time of screening.

         22. Life expectancy &lt; 12 months due to non-cardiac comorbid conditions.

         23. Subjects in whom anti-platelet and/ or anticoagulant therapy is contraindicated, or
             who will refuse transfusion.

         24. Subjects who have active bacterial endocarditis or other active infections.

         25. Currently participating in an investigational drug or another device study.

         26. Subjects who have a planned treatment with any other investigational device or
             procedure during the study follow-up period (30 days).

         27. Subjects with planned concomitant surgical or transcatheter ablation for Atrial
             fibrillation during the study follow-up period (30 days).

         28. Any subject with a balloon valvuloplasty (BAV) within 30 days of the procedure.

         29. Subject is a woman of child bearing age.

         30. Patient with Heparin-Induced Thrombocytopenia Syndrome.

         31. Inner diameter of aortic arch is less than 25mm.

         32. Type I Aortic Arch: Distance of the origin of the innominate artery from the top of
             aortic arch is less than one times the diameter of left common carotid artery.

         33. Brachiocephalic trunk originating from the aortic arch that splits into the bilateral
             subclavian arteries and a bicarotid trunk (Origin D).

        Neurological:

          1. Subject has active major psychiatric disease.

          2. Subject has severe visual, auditory, or learning impairment and is unable to
             comprehend English or local language and therefore unable to be consented for the
             study.

          3. Subjects with neurodegenerative or other progressive neurological disease or history
             of significant head trauma followed by persistent neurologic defaults or known
             structural brain abnormalities.

        Angiographic:

          1. Excessive tortuosity in the left radial/ brachial/subclavian artery preventing
             ProtEmbo System access and insertion.

          2. Subject whose left radial/ brachial/ subclavian artery reveals significant stenosis,
             calcification, ectasia, dissection, or aneurysm.

        Magnetic Resonance Imaging:

          1. Subject Body Mass Index (BMI) precluding imaging in scanner.

          2. Contraindications to MRI (subjects with any implantable temporary or permanent
             pacemaker or defibrillator, metal implants in field of view, metallic fragments,
             clips, or devices in the brain or eye before TAVR procedure).

          3. Patients who have a high risk of complete AV block after TAVR, with the need of
             permanent pacemaker (e.g. patients with pre-existing bifascicular block or complete
             right bundle branch block plus any degree of AV block).

          4. Planned implantation of a pacemaker or defibrillator implantation within the first 7
             days after TAVR.

          5. Claustrophobia precluding MRI scanning.

          6. No scanner hardware, software, coil or protocol changes should occur during the course
             of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James C. Leiter, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>MAXIS, LLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Karl von Mangoldt</last_name>
    <phone>+49 241 99033622</phone>
    <email>info@protembis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Conrad Rasmus</last_name>
    <phone>+49 241 99033622</phone>
    <email>info@protembis.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Cardiology Galway University Hospital and SAOLTA Healthcare Group</name>
      <address>
        <city>Galway</city>
        <state>County Galway</state>
        <zip>H91HHTO</zip>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Darren Mylotte, M.D.</last_name>
      <phone>+353 86 0233886</phone>
      <email>Darren.mylotte@hse.ie</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pauls Stradins Clinical University Hospital</name>
      <address>
        <city>Riga</city>
        <zip>LV1002</zip>
        <country>Latvia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrejs Erglis, M.D.</last_name>
      <phone>+371 (670) 69-541</phone>
      <email>a.a.erglis@stradini.lv</email>
    </contact>
  </location>
  <location_countries>
    <country>Ireland</country>
    <country>Latvia</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 13, 2017</study_first_submitted>
  <study_first_submitted_qc>October 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 30, 2017</study_first_posted>
  <last_update_submitted>October 24, 2017</last_update_submitted>
  <last_update_submitted_qc>October 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stroke prevention</keyword>
  <keyword>embolic protection</keyword>
  <keyword>cognition</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

